MULTIPLE SCLEROSIS JOURNAL
Nelly Siller, Jens Kuhle, Muthuraman Muthuraman, Christian Barro, Timo Uphaus,
Sergiu Groppa, Ludwig Kappos, Frauke Zipp and Stefan Bittner
Multiple Sclerosis Journal
Abstract:
Background: Monitoring neuronal injury remains one key challenge in early relapsing-remitting multiple
sclerosis (RRMS) patients. Upon axonal damage, neurofilament – a major component of the neuroaxonal
cytoskeleton – is released into the cerebrospinal fluid (CSF) and subsequently peripheral blood.
Objective: To investigate the relevance of serum neurofilament light chain (sNfL) for acute and chronic
axonal damage in early RRMS.
Methods: sNfL levels were determined in 74 patients (63 therapy-naive) with recently diagnosed clinically
isolated syndrome (CIS) or RRMS using Single Molecule Array technology. Standardized 3 T magnetic
resonance imaging (MRI) was performed at baseline and 1–3 consecutive follow-ups (42 patients;
range: 6–37 months).
Results: Baseline sNfL correlated significantly with T2 lesion volume (r = 0.555, p < 0.0001). There was
no correlation between baseline sNfL and age, Expanded Disability Status Scale (EDSS) score or other
calculated MRI measures. However, T2 lesion volume increased (r = 0.67, p < 0.0001) and brain parenchymal
volume decreased more rapidly in patients with higher baseline sNfL (r = −0.623, p = 0.0004).
Gd-enhancing lesions correlated positively with sNfL levels. Initiation of disease-modifying treatment
led to a significant decrease in sNfL levels.
Conclusion: sNfL indicates acute inflammation as demonstrated by correlation with Gd+ lesions. It is
a promising biomarker for neuro-axonal damage in early multiple sclerosis (MS) patients, since higher
baseline sNfL levels predicted future brain atrophy within 2 years.
Related Posts
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…